A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, With an Active-Treatment Dose-Blinded Period, to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects With Parkinson's Disease

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, With an Active-Treatment Dose-Blinded Period, to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects With Parkinson's Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Jun 2018

At a glance

  • Drugs BIIB 054 (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions
  • Acronyms SPARK
  • Sponsors Biogen
  • Most Recent Events

    • 25 Jan 2018 According to a Neurimmune Therapeutics media release, first patient has been dosed.
    • 18 Dec 2017 Planned End Date changed from 30 Sep 2021 to 30 Jun 2022.
    • 18 Dec 2017 Planned primary completion date changed from 30 Sep 2021 to 30 Apr 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top